Thus, ESR1 mutation detection is expected to become a prognostic and predictive biomarker in the near future, to be used in clinical practice for hormone-receptor positive (HR+) breast cancer, especially in the metastatic setting [4,5]. The gene discussed is ESR1; the disease is breast carcinoma.